Paxlovid Gets FDA Panel Backing For Full Approval; Combating Rebound Misperception Urged

 
• By Brenda Sandburg
Paxlovid box and pills
FDA panel finds Paxlovid benefit-risk is favorable for treatment of COVID-19 in those at high-risk of progresing to severe illness • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers